Mieloma, amiloidosis, macroglobulinemia y otras gammapatías
Publicaciones destacadas
-
Clonotypic characterization defines B-cell drivers of clonal expansion and intratumor heterogeneity in IgM monoclonal gammopathies
Moreno, David F; Nadeu, Ferran; Casado-Pelaez, Marta; Mata, Caterina; Marquez-Lopez, Ian;(...)Colomer, Dolors; Rosinol, Laura; van Boxtel, Ruben; Esteller, Manel; de Larrea, Carlos Fernandez.Referencia:HemaSphere 2026.
-
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain
Cardus, Oriol; Mane Pujol, Joan; De Daniel, Anna; Moreno, David F; Oliveira, Theo Gremen M;(...)Munarriz, Daniel; Juan, Manel; Urbano-Ispizua, Alvaro; Rodriguez-Lobato, Luis Gerardo; Fernandez De Larrea, Carlos.Referencia:Journal for ImmunoTherapy of Cancer 2026.
-
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Lahuerta, Juan Jose; San-Miguel, Jesus; Jimenez-Ubieto, Ana; Alonso, Rafael; Paiva, Bruno;(...)de la Cruz, Javier; Mateos, Maria Victoria; Rosinol, Laura; Blade, Joan; Spanish Myeloma Grp.Referencia:BLOOD 2025.
-
Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Rodriguez-Lobato, Luis Gerardo; Cardus, Oriol; Mane-Pujol, Joan; Battram, Anthony M; Vaque-Salsench, Sergi;(...)Blade, Joan; Juan, Manel; Urbano-Ispizua, Alvaro; Engel, Pablo; Fernandez de Larrea, Carlos.Referencia:Cancer Immunology Research 2025.
-
Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
Rodriguez-Lobato, Luis Gerardo; de Daniel, Anna; Pereira, Arturo; de Larrea, Carlos Fernandez; Tovar, Natalia;(...)Llobet, Noemi; Carcelero, Esther; Munarriz, Daniel; Blade, Joan; Rosinol, Laura.Referencia:Blood Cancer Journal 2025.
-
Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells
Battram, Anthony M; Mane-Pujol, Joan; Moreno, David F; Oliver-Caldes, Aina; Carpio, Judit;Cardus, Oriol; Rodriguez-Lobato, Luis Gerardo; Urbano-Ispizua, Alvaro; de Larrea, Carlos Fernandez.Referencia:BLOOD ADVANCES 2025.
-
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
Zugas, Ines; Tormo-Ratera, Marta; Oliver-Caldes, Aina; Soler-Perromat, Juan Carlos; Gonzalez-Calle, Veronica;(...)Martinez-Lopez, Joaquin; Mateos, Maria-Victoria; Tomas, Xavier; Setoain, Xavier; de Larrea, Carlos Fernandez.Referencia:BLOOD ADVANCES 2025.
-
Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma.
Oliver-Caldes, Aina; Espanol-Rego, Marta; Zabaleta, Aintzane; Gonzalez-Calle, Veronica; Navarro-Velazquez, Sergio;(...)Mateos, Maria Victoria; Urbano-Ispizua, Alvaro; Paiva, Bruno; Pascal, Mariona; de Larrea, Carlos Fernandez.Referencia:CLINICAL CANCER RESEARCH 2024.
-
The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
de Daniel, Anna; Rodriguez-Lobato, Luis Gerardo; Tovar, Natalia; Cibeira, M Teresa; Moreno, David F;(...)Isola, Ignacio; Lozano, Ester; Blade, Joan; Rosinol, Laura; de Larrea, Carlos Fernandez.Referencia:HemaSphere 2024.
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CART-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA- HCB-01): a single-arm, multicentre, academic pilot study
Oliver-Caldes, Aina; Gonzalez-Calle, Veronica; Cabanas, Valentin; Espanol-Rego, Marta; Rodriguez-Otero, Paula;(...)Moraleda, Jose M; Mateos, Maria-Victoria; Pascal, Mariona; Urbano-Ispizua, Alvaro; de Larrea, Carlos Fernandez.Referencia:LANCET ONCOLOGY 2023.
